| GTO ID | GTC2449 |
| Trial ID | NCT04539366 |
| Disease | Osteosarcoma | Neuroblastoma |
| Altered gene | GD2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | GD2 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial |
| Year | 2020 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2020-06646|NCI-2020-06646|PED-CITN-02|PED-CITN-02|P30CA015704|U24CA224309|UM1CA154967 |
| Cohort 1 | |||||||||||
|
|||||||||||